Broderick Brian C Raised By $309,372 Its United Technologies (UTX) Position; Last Week BioMarin Pharmaceutical Inc. (BMRN) Analysts

January 14, 2018 - By Clifton Ray

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 20 have Buy rating, 0 Sell and 7 Hold. Therefore 74% are positive. BioMarin Pharmaceutical had 76 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Jefferies on Tuesday, August 25. Gabelli initiated the shares of BMRN in report on Thursday, December 8 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, August 5 report. Piper Jaffray maintained the stock with “Overweight” rating in Friday, August 5 report. Wedbush maintained the stock with “Hold” rating in Wednesday, August 5 report. On Friday, February 26 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was maintained by Wedbush on Monday, October 5 with “Neutral”. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Outperform” rating given on Thursday, April 7 by BMO Capital Markets. J.P. Morgan maintained the stock with “Buy” rating in Tuesday, July 11 report. Wedbush maintained the stock with “Hold” rating in Wednesday, November 15 report. See BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) latest ratings:

20/12/2017 Broker: Wedbush Rating: Buy New Target: $110.0 Maintain
14/12/2017 Broker: Wedbush Old Rating: Neutral New Rating: Outperform Upgrade
15/11/2017 Broker: Wedbush Rating: Hold New Target: $108.0 Maintain
27/10/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $117 New Target: $119 Maintain
27/10/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $107 New Target: $105 Maintain
19/10/2017 Broker: SunTrust Rating: Buy New Target: $115.0 Maintain
18/10/2017 Broker: Cowen & Co Rating: Buy New Target: $150.0 Maintain
19/10/2017 Broker: Credit Suisse Rating: Buy New Target: $124.0 Maintain
19/10/2017 Broker: Leerink Swann Rating: Buy New Target: $142.0 Maintain
18/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $107.0 Maintain

Broderick Brian C increased United Technologies (UTX) stake by 6.16% reported in 2017Q3 SEC filing. Broderick Brian C acquired 2,667 shares as United Technologies (UTX)’s stock rose 8.03%. The Broderick Brian C holds 45,990 shares with $5.34M value, up from 43,323 last quarter. United Technologies now has $109.07 billion valuation. The stock increased 1.18% or $1.59 during the last trading session, reaching $136.58. About 5.21M shares traded or 67.82% up from the average. United Technologies Corporation (NYSE:UTX) has risen 22.99% since January 14, 2017 and is uptrending. It has outperformed by 6.29% the S&P500.

Since September 15, 2017, it had 0 buys, and 8 selling transactions for $6.38 million activity. Shares for $1.70M were sold by BAFFI ROBERT on Thursday, September 28. BIENAIME JEAN JACQUES sold $903,203 worth of stock or 10,000 shares. LAWLIS V BRYAN also sold $333,150 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, January 2. FUCHS HENRY J sold 15,000 shares worth $1.34 million. 800 shares were sold by HERON ELAINE J, worth $71,116 on Thursday, December 14. On Friday, September 22 Ajer Jeffrey Robert sold $334,495 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 3,521 shares.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $15.85 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.13, from 1.26 in 2017Q2. It dived, as 40 investors sold BioMarin Pharmaceutical Inc. shares while 116 reduced holdings. 45 funds opened positions while 132 raised stakes. 171.51 million shares or 2.04% more from 168.09 million shares in 2017Q2 were reported. Exane Derivatives holds 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 172 shares. Gideon Capital Advsrs Inc reported 4,398 shares stake. First Personal owns 514 shares. Greenwood Associate Ltd Limited Liability Company has invested 0.13% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). 270,558 were accumulated by Asset Mgmt One Ltd. Apg Asset Mgmt Nv invested 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Ardsley Advisory Prtn, Connecticut-based fund reported 7,000 shares. 73,226 are owned by Stanley. Kbc Gp Nv holds 0.31% or 366,872 shares in its portfolio. D E Shaw Communication owns 91,792 shares for 0.01% of their portfolio. Bain Capital Pub Equity Mgmt Limited Liability Company reported 244,045 shares stake. Scout Invs holds 0.39% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 151,456 shares. Goldman Sachs Group Incorporated invested in 2.36 million shares or 0.05% of the stock. Cambridge Investment Rech Advsrs reported 2,537 shares. Guggenheim Cap Ltd Liability Corporation, a Illinois-based fund reported 148,157 shares.

The stock increased 0.27% or $0.24 during the last trading session, reaching $90.22. About 874,426 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since January 14, 2017 and is uptrending. It has underperformed by 11.41% the S&P500.

Since December 13, 2017, it had 0 insider purchases, and 3 selling transactions for $734,561 activity. Amato Elizabeth B sold $546,600 worth of United Technologies Corporation (NYSE:UTX) on Friday, December 15. $79,088 worth of United Technologies Corporation (NYSE:UTX) was sold by Bailey Robert J. on Wednesday, December 13.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>